NO20093194L - Vektor for uttrykkelse av en sekvens som koder for et cytotoksisk genprodukt, og anvendelse av denne for a fremstille et medikament for behandling av cancer - Google Patents
Vektor for uttrykkelse av en sekvens som koder for et cytotoksisk genprodukt, og anvendelse av denne for a fremstille et medikament for behandling av cancerInfo
- Publication number
- NO20093194L NO20093194L NO20093194A NO20093194A NO20093194L NO 20093194 L NO20093194 L NO 20093194L NO 20093194 A NO20093194 A NO 20093194A NO 20093194 A NO20093194 A NO 20093194A NO 20093194 L NO20093194 L NO 20093194L
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- treatment
- expressing
- drug
- vector
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 231100000433 cytotoxic Toxicity 0.000 title abstract 2
- 230000001472 cytotoxic effect Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Oppfinnelsen vedrører spesifikk ekspresjon av heterologe sekvenser, spesielt gener som koder for cytotoksiske produkter, i tumorceller under kontroll av regulatoriske transkripsjonelle sekvenser. Spesielt foretrukket promotere inkluderer HI 9 regulatoriske sekvenser, IGF-1 promoter og IGF-2 P3 og P4 promotere. Oppfinnelsen tilveiebringer ekspresjonskonstruksjoner og metoder for administrering av slike ekspresjonskonstruksjoner. Sammensetningene og metodene fra oppfinnelsen er nyttige i behandling av cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94360897A | 1997-10-03 | 1997-10-03 | |
PCT/IL1998/000486 WO1999018195A2 (en) | 1997-10-03 | 1998-10-04 | Methods and compositions for inducing tumor-specific cytotoxicity |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20093194L true NO20093194L (no) | 2000-06-02 |
NO331723B1 NO331723B1 (no) | 2012-03-05 |
Family
ID=25479934
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20001684A NO328470B1 (no) | 1997-10-03 | 2000-03-31 | Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer. |
NO20093194A NO331723B1 (no) | 1997-10-03 | 2009-10-22 | Vektor som kan utrykke et cytotoksisk genprodukt samt anvendelse av en slik vektor for fremstilling av et preparat for behandling av kreft |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20001684A NO328470B1 (no) | 1997-10-03 | 2000-03-31 | Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer. |
Country Status (17)
Country | Link |
---|---|
US (2) | US6087164A (no) |
EP (1) | EP1019499B1 (no) |
JP (3) | JP5153031B2 (no) |
KR (1) | KR100524262B1 (no) |
CN (1) | CN1229496C (no) |
AT (1) | ATE407948T1 (no) |
AU (1) | AU755774B2 (no) |
BR (1) | BR9812717B1 (no) |
CA (1) | CA2308124C (no) |
CZ (2) | CZ294941B6 (no) |
DE (1) | DE69840001D1 (no) |
HU (1) | HU228470B1 (no) |
IL (1) | IL135430A0 (no) |
NO (2) | NO328470B1 (no) |
PL (1) | PL339949A1 (no) |
RU (1) | RU2214280C2 (no) |
WO (1) | WO1999018195A2 (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040006220A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of insulin-like growth factor 2 expression |
US7041654B2 (en) | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
CA2365901A1 (en) * | 1999-04-14 | 2000-10-19 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
DE19928342A1 (de) * | 1999-06-21 | 2000-12-28 | Deutsches Krebsforsch | Vektoren zur gentherapeutischen Tumorbehandlung |
US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
WO2002046449A2 (en) * | 2000-12-07 | 2002-06-13 | The Penn State Research Foundation | Selection of catalytic nucleic acids targeted to infectious agents |
US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US20040005567A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of cyclin-dependent kinase 4 expression |
AU2003241985A1 (en) * | 2002-05-31 | 2003-12-19 | Medinet Co., Ltd. | Dna inducing cancer cell-specific expression and cancer cell-specific expression vector |
US20040180844A1 (en) * | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
US20040220085A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Compositions for nucleic acid delivery |
US20040219099A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Method for the treatment of tumors |
US7482156B2 (en) * | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
US7063947B2 (en) * | 2004-04-08 | 2006-06-20 | Promogen, Inc. | System for producing synthetic promoters |
US7429482B2 (en) * | 2005-01-13 | 2008-09-30 | United States Of America As Represented By The Department Of Veterans Affairs | Screening tools for discovery of novel anabolic agents |
EP1915448B1 (en) | 2005-07-07 | 2013-09-04 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Nucleic acid agents for downregulating h19, and methods of using same |
DE602006014009D1 (de) | 2005-09-22 | 2010-06-10 | Yissum Res Dev Co | Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs |
CA2675967A1 (en) * | 2007-01-16 | 2008-07-24 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Nucleic acid constructs and methods for specific silencing of h19 |
CA2715080C (en) | 2007-09-28 | 2021-09-28 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
WO2009053982A1 (en) * | 2007-10-25 | 2009-04-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Constructs containing multiple expression cassettes for cancer therapy |
EP2298866A4 (en) * | 2008-07-02 | 2013-11-20 | Otsuka Pharma Co Ltd | ARTIFICIAL KIDNEY PRECURSOR AND METHOD FOR PRODUCING THE SAME |
US8492133B2 (en) | 2009-01-20 | 2013-07-23 | Ramot At Tel Aviv University, Ltd. | MIR-21 promoter driven targeted cancer therapy |
EA016223B1 (ru) * | 2009-10-07 | 2012-03-30 | Учреждение Российской Академии Наук Институт Молекулярной Генетики Ран | Способ и генная конструкция для высокоспецифичного ингибирования нежелательного роста клеток |
WO2016178233A1 (en) * | 2015-05-05 | 2016-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Nucleic acid-cationic polymer compositions and methods of making and using the same |
BR112020021962A2 (pt) * | 2018-04-30 | 2021-01-26 | Amicus Therapeutics, Inc. | construtos para terapia gênica e métodos de uso |
CN110714075B (zh) * | 2018-07-13 | 2024-05-03 | 立森印迹诊断技术(无锡)有限公司 | 一种用于检测肺肿瘤良恶性程度的分级模型及其应用 |
CN111206093A (zh) * | 2018-11-21 | 2020-05-29 | 立森印迹诊断技术(无锡)有限公司 | 一种用于检测浸润性膀胱癌的标志物及其应用 |
CN109609505A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院成都生物研究所 | 一种体内筛选的剪切rna的锤头状核酶 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2699191B1 (fr) * | 1992-12-16 | 1995-02-10 | Univ Paris Curie | Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs. |
US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
IL108879A (en) * | 1994-03-07 | 2000-08-31 | Yissum Res Dev Co | Diagnostic assay for malignancies using the H19 gene and kit |
FR2723697B1 (fr) * | 1994-08-17 | 1996-09-20 | Rhone Poulenc Rorer Sa | Methode de traitement de la restenose par la therapie genique |
FR2725213B1 (fr) * | 1994-10-04 | 1996-11-08 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation en therapie genique |
-
1998
- 1998-10-01 US US09/165,240 patent/US6087164A/en not_active Expired - Lifetime
- 1998-10-04 HU HU0003745A patent/HU228470B1/hu unknown
- 1998-10-04 CA CA002308124A patent/CA2308124C/en not_active Expired - Lifetime
- 1998-10-04 AT AT98947759T patent/ATE407948T1/de not_active IP Right Cessation
- 1998-10-04 BR BRPI9812717-9A patent/BR9812717B1/pt not_active IP Right Cessation
- 1998-10-04 WO PCT/IL1998/000486 patent/WO1999018195A2/en active IP Right Grant
- 1998-10-04 CZ CZ2004741A patent/CZ294941B6/cs not_active IP Right Cessation
- 1998-10-04 CZ CZ20001201A patent/CZ294694B6/cs not_active IP Right Cessation
- 1998-10-04 DE DE69840001T patent/DE69840001D1/de not_active Expired - Lifetime
- 1998-10-04 AU AU94571/98A patent/AU755774B2/en not_active Expired
- 1998-10-04 PL PL98339949A patent/PL339949A1/xx unknown
- 1998-10-04 IL IL13543098A patent/IL135430A0/xx active IP Right Grant
- 1998-10-04 JP JP2000514993A patent/JP5153031B2/ja not_active Expired - Lifetime
- 1998-10-04 RU RU2000111553/14A patent/RU2214280C2/ru active
- 1998-10-04 EP EP98947759A patent/EP1019499B1/en not_active Expired - Lifetime
- 1998-10-04 CN CNB988118335A patent/CN1229496C/zh not_active Expired - Lifetime
- 1998-10-04 KR KR10-2000-7003609A patent/KR100524262B1/ko not_active IP Right Cessation
-
2000
- 2000-03-31 NO NO20001684A patent/NO328470B1/no not_active IP Right Cessation
- 2000-05-10 US US09/568,059 patent/US6306833B1/en not_active Expired - Lifetime
-
2006
- 2006-05-24 JP JP2006144648A patent/JP2006304801A/ja not_active Withdrawn
-
2007
- 2007-10-18 JP JP2007270777A patent/JP2008136480A/ja active Pending
-
2009
- 2009-10-22 NO NO20093194A patent/NO331723B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20093194L (no) | Vektor for uttrykkelse av en sekvens som koder for et cytotoksisk genprodukt, og anvendelse av denne for a fremstille et medikament for behandling av cancer | |
DK0556345T3 (da) | Retrovirale vektorer,som er egnede til genterapi | |
GB8717430D0 (en) | Recombinant dna product | |
DE69331526T2 (de) | Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel | |
EP0844887A4 (en) | THE TRANSDUCTION OF MYOBLASTEN BY VECTORS FROM ADENO-ASSOCIATED VIRUSES | |
HUT68261A (en) | Synthetic dna sequence having enhanced insecticidal activity in maize | |
ATE85081T1 (de) | Analoge des gewebespezifischen plasminogenaktivators. | |
BR9612359A (pt) | Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos | |
WO1997022695A3 (fr) | Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer | |
NO970312L (no) | Karbonmonoksidavhengige guanylylcyklase modifiseringsmidler | |
WO1995034669A3 (en) | Retroviral gene therapy vectors and therapeutic methods based thereon | |
IL117194A0 (en) | Amplifying sequences vectors comprising them and their uses in compositions for the expression of nucleotide sequences and pharmaceutical compositions containing them | |
ATE221124T1 (de) | Kombinationsvektoren zum austragen von genmaterial | |
ATE314481T1 (de) | Promotor des transaldolase-genes von k.lactis und dessen verwendung | |
DE69631041D1 (de) | Promotor des utrophingens | |
WO2001081404A3 (en) | INDUCIBLE PLASMID VECTOR ENCODING TGF-β AND USES THEREOF | |
WO1996033282A3 (en) | High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations | |
HUP0004857A2 (hu) | T. variabilisból származó D-aminosav oxidáz promótere | |
Shokoohi et al. | Chimeric Antigen Receptor Delivery Approaches in the Era of Regulatory-Approved T-cell Products for Cancer Immunotherapy | |
WO2000078939A3 (de) | Vektoren zur gentherapeutischen tumorbehandlung | |
DE59310334D1 (de) | Vektor zur expression von therapeutisch relevanten genen | |
YU66200A (sh) | Humani bmp-4 promotor i postupak za istraživanje supstance koja je vezana sa kostima pomoću primene istog | |
Seth | SYNTHESIS AND USE OF DEOXYOLIGORIBONUCLEOTIDES FOR THE STUDY OF SPECIFIC INITIATION OF PROTEIN SYNTHESIS AND EXPRESSION OF EUKARYOTIC GENES IN BACTERIA. | |
TW200504217A (en) | Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |